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SUMMARY
The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show promising results, but drug resistance often limits durable clinical responses. There is a need for in vivo systems that allow for mechanistic drug resistance studies and (combinatorial) treatment optimization. Therefore, we established a large collection of patientderived xenografts (PDXs), derived from BRAF V600E , NRAS Q61 , or BRAF WT /NRAS WT melanoma metastases prior to treatment with BRAF inhibitor and after resistance had occurred. Taking advantage of PDXs as a limitless source, we screened tumor lysates for resistance mechanisms. We identified a BRAF V600E protein harboring a kinase domain duplication (BRAF V600E/DK ) in $10% of the cases, both in PDXs and in an independent patient cohort. While BRAF V600E/DK depletion restored sensitivity to BRAF inhibition, a pan-RAF dimerization inhibitor effectively eliminated BRAF V600E/DK -expressing cells. These results illustrate the utility of this PDX platform and warrant clinical validation of BRAF dimerization inhibitors for this group of melanoma patients.
INTRODUCTION
Until 5 years ago, treatment options for metastatic melanoma were limited to chemotherapy, which did not significantly improve patient survival. However, the genetic characterization of melanoma (Davies et al., 2002) has prompted the development of therapies targeting specifically the oncogenic drivers of the disease. Approximately half of the patients diagnosed with metastatic melanoma harbor an activating mutation in BRAF, most commonly T1799A. This encodes the BRAF V600E protein, which renders these patients eligible for treatment with selective BRAF inhibitors. In clinical trials, the first of these inhibitors, vemurafenib, elicited partial or complete tumor regression in the majority of patients (Chapman et al., 2011; Flaherty et al., 2010) .
Despite these promising results, while some patients show remarkable durable responses to BRAF inhibition (BRAFi), the majority show an initial response to vemurafenib but eventually develop resistance (Solit and Rosen, 2014) . Accounting for this are a plethora of resistance mechanisms, including reactivation of the MAPK pathway, the PI3K/AKT pathway, or both Shi et al., 2012 Shi et al., , 2014a Das Thakur et al., 2013; Wagle et al., 2011) . As the majority of resistance mechanisms cause reactivation of the MAPK pathway (Van Allen et al., 2014) , a logical next step was to determine the clinical benefit of combinatorial treatment of a MEK inhibitor (e.g., trametinib or cobimetinib) with a BRAF inhibitor (vemurafenib or dabrafenib) . The response to such combined treatment was significantly more durable than what was seen for single BRAFi (Larkin et al., 2014; Robert et al., 2015) . Still also in the combination treatment setting, resistance again limited overall survival benefit Wagle et al., 2014) . Because of these major challenges, there is a dire need to develop more effective (combinatorial) treatment regimens.
Resistance to targeted drugs is mostly studied in in vitro cell models (Basile et al., 2012; Vergani et al., 2011) , but the use of long-term cultured cancer cell lines has several limitations. First, they do not reliably predict the clinical effect of therapeutics (Burchill, 2006; Voskoglou-Nomikos et al., 2003) . Second, the monolayer character of cell culture does not recapitulate the 3D interactions between stromal and cancer cells, which influence not only the dynamics of tumor progression but also therapy response (Straussman et al., 2012) . Moreover, the establishment of 2D cell lines from human cancers can induce irreversible changes, including genetic aberrations (De Witt Hamer et al., 2008) , alterations in gene expression (Daniel et al., 2009) , or dependencies on certain signaling pathways (Clement et al., 2007) . Importantly, these properties are not restored upon xenografting of cell lines (Daniel et al., 2009) .
A clinically useful model would therefore be to implant tumor fragments derived from patients immediately into mice, thereby cancelling the opportunity for tumors to acquire alterations resulting from in vitro culturing. Such patient-derived xenografts (PDXs) already have been established for several tumor types, including colon cancer (Bertotti et al., 2011) , pancreatic cancer (Rubio-Viqueira et al., 2006) , breast cancer (DeRose et al., 2011) , and melanoma (Einarsdottir et al., 2014; Girotti et al., 2016; Monsma et al., 2015; Das Thakur et al., 2013) . Some of these PDX models proved successful in large-scale assessment of the effect of several (combinatorial) therapies and to identify stratification markers, discriminating subgroups of tumors divergently responding to targeted therapy (Bertotti et al., 2011; Gao et al., 2015) .
Therefore, we have established a model for metastatic melanoma in which the complex interactions between tumors and at least some components of the tumor microenvironment are maintained. Here we present a collection comprising 89 PDXs established from human metastatic melanomas, which were acquired either before the start of therapy or after the emergence of resistance. This comprehensive PDX platform was analyzed for biomarkers, chromosomal aberrations, RNA expression profiles, mutational spectrum, genetic heterogeneity, and targeted drug resistance patterns. In addition, we tested the utility of this platform as a limitless source of patients' tumor material by screening for resistance mechanisms. Collectively, our results demonstrate that this platform is highly suitable for studying resistance, discovering additional drug targets for companion treatment, and for preclinical studies of human melanoma in general. (Table S1 ). Our attempt to generate cell lines from these PDX samples was successful in 30% of the cases (Table S1) . After a first passage in mice (.X1), tumor fragments or digests could be propagated in vivo (.X2, Figure 1A) or cryopreserved for later use. Passaging in mice led to a gradual increase in the tumor outgrowth kinetics ( Figure 1B) , probably due to loss of human stromal components, consistent with PDXs derived from other tumor types (DeRose et al., 2011; Monsma et al., 2012) .
RESULTS

Establishment of a PDX Platform for Metastatic
Stable Melanoma Marker Expression, Chromosomal Aberrations, and Gene Expression upon In Vivo Passaging of PDXs We next determined the effect of passaging PDXs in vivo on melanoma marker expression, chromosomal aberrations, and RNA profiles. First, immunohistochemistry (IHC) for melanoma markers Melan-A, S100, gp-100, and tyrosinase, commonly used for the clinical diagnosis of melanoma, showed that melanoma marker expression remained stable when the patient's tumor was compared to two consecutive passages in vivo as PDXs ( Figure 1C ; Figure S1 ).
Second, chromosomal aberrations, analyzed by array comparative genomic hybridization (array CGH), revealed that the genetic heterogeneity was captured in the PDXs ( Figures  1D and 1E ): passaging of M013 in mice revealed that at least some of the genetic aberrations found in the parental tumor were heterogeneous. For instance, the loss of chromosome 10, which was observed in the patient's tumor, could be detected in one of three first-passage PDXs only, suggesting that chromosome 10 had not been lost in all parental tumor cells (Figure 1D) . This is consistent with recent studies by us and others showing that melanomas are highly heterogeneous Shi et al., 2014b; Van Allen et al., 2014) . Also passaging of M003 in mice revealed a variable pattern, which can be explained either by heterogeneity in the original tumor or by loss of genomic variation upon in vivo passaging. Importantly, after the first passage, the chromosomal content was stable and highly similar to the parental chromosomal content ( Figure 1E ).
Third, we analyzed gene expression patterns, comparing patient samples to their corresponding PDXs. We obtained samples for PDX establishment from four different patients, with tumor samples taken either before the start of vemurafenib treatment or after a patient had acquired therapy resistance (indicated by R). RNA was isolated from both patients' tumors and PDXs and gene expression profiling was done by RNA sequencing. Hierarchical clustering of all samples was performed, resulting in a clustering that revealed a high concordance in gene expression between the patient samples and their corresponding PDXs ( Figure 1F) .
Together, these data show that, during the passaging of human melanomas in mice, the phenotypic and genetic characteristics are well preserved, yielding a collection of PDXs closely resembling the original patients' tumors.
Clinical History of Patients from Matched Pre-and Postvemurafenib PDX Pairs
We acquired a set of six matched PDX pairs, representing tumor material from patients both before the start of treatment with vemurafenib and after resistance had occurred (indicated by R). We illustrated the treatment schedule, the location of the lesion from where material was obtained for xenografting, and the specific response of these lesions to vemurafenib in Figure S2 . In four patients, the resistant lesions, from which post-treatment PDXs were derived, either initially responded to vemurafenib before acquiring resistance (M009R, M026R, and M048R1; Figure S2) or emerged as new lesions during treatment (M029R and M048R2; Figure S2 ). Therefore, this group of PDXs was labeled acquired resistant. One matched pair (M005) was derived from a patient who was still responding to vemurafenib when the posttreatment sample was obtained, and was therefore categorized as on treatment. The sixth PDX pair was acquired from a patient (M019) who progressed immediately on vemurafenib treatment, qualifying these melanomas as intrinsic resistant ( Figure S2 ). (C) H&E stainings and IHC stainings for MelanA, S100, gp-100, and tyrosinase were performed on the parental tumor and two subsequent passages of PDXs (X1 and X2). Scale bars indicate 100 mm.
(D) Copy-number profiles, based on array CGH, show the parental tumor (P) M013 and two PDX passages (the X2 passage was established from the third X1 PDX).
(E) Copy-number profiles, based on array CGH, show the parental tumor (P) M003 and two PDX passages (the X2 passages are next to their own X1-passaged PDX). Blue, deletion; red, amplification. (F) Hierarchical clustering of RNA-sequencing data performed on patient samples and PDXs derived of these samples, after filtering as described in the Supplemental Experimental Procedures, is shown.
Vemurafenib-Resistant PDXs
Commonly Display MAPK Pathway Reactivation Several groups, including ours, have demonstrated that the MAPK pathway and, to a lesser extent, the PI3K pathway are commonly reactivated in vemurafenib-resistant melanomas Shi et al., 2014b; Van Allen et al., 2014) . To determine whether this was recapitulated in our matched PDX series, we performed immunoblotting for phosphorylated ERK (p-ERK) and AKT (p-AKT). Indeed, all four acquired resistant PDXs from the matched pair set had reactivated p-ERK (Figure 2A ), which was confirmed by IHC ( Figure S3A ). Only one PDX pair, namely M048, also showed reactivated p-AKT ( Figure 2A ). As expected, the PDX of the intrinsically resistant patient M019 already showed elevated p-ERK and p-AKT levels in the pre-treatment setting, while p-ERK was relatively low in the PDX from the on-treatment patient ( Figure 2A ; Figure S3A ).
Previously, we and others have shown that acquired resistance to BRAFi is effectively brought about by the loss of expression of microphthalmia-associated transcription factor (MITF) (Konieczkowski et al., 2014; M€ uller et al., 2014) . Consistent with this, we observed decreased expression of MITF in three acquired resistant post-vemurafenib PDXs (legend continued on next page) (M009R.X1, M026R.X1, and M048R.X1; Figure 2A ). Reduced expression of MITF coincides with upregulation of one or multiple receptor tyrosine kinases (RTKs), such as EGFR, PDGFR, and, most commonly, AXL (Konieczkowski et al., 2014; M€ uller et al., 2014) , which was well recapitulated in these matched acquired resistant PDXs (Figure 2A ). Only M029R.X1 displayed increased expression of MITF expression upon acquired resistance (Figure 2A ), which also previously has been reported as a resistance mechanism to MAPK pathway inhibition (Garraway et al., 2005; M€ uller et al., 2014) .
In conclusion, our series of matched PDXs captures the resistance biomarkers that are commonly seen in drug-resistant melanomas in patients.
Identification of Resistance Mechanisms in Matched PDX Pairs
To uncover the cause of resistance in the matched PDX pairs, we performed whole-exome sequencing (WES) on genomic DNA (gDNA) derived from all matched PDXs. The level of tumor infiltration by mouse stroma was determined by a mouse pathologist via analysis of formalin-fixed paraffinembedded (FFPE) H&E stainings of these PDXs, revealing that most PDXs contained >80% of tumor cells (Table S2) . XenofilteR (R.J.C.K. and O.K., unpublished data) was used to remove all sequence reads that originated from mouse DNA. Copy-number profiles were generated from the filtered WES data by CopywriteR (Figure 2B ). This analysis revealed that pre-and post-vemurafenib PDXs had highly similar DNA copy-number profiles, although some variation was observed. This could result from inter-tumor heterogeneity, as most pre-and post-vemurafenib PDXs were not derived from the same patient lesion ( Figure S2B ). When analyzing copy-number aberrations (CNAs) in more detail, we detected a BRAF T1799A amplification, an established resistance mechanism (Shi et al., 2014b; Das Thakur et al., 2013; Van Allen et al., 2014) , in the resistant M009R.X1, but not in the pre-treatment PDX ( Figure 2C , top panel). This amplification was validated by qPCR on gDNA ( Figure 2C , bottom panel). None of the other resistant PDXs displayed an amplification of BRAF T1799A (Figures S3B and S3C). Next we analyzed the presence of mutations in the matched PDX pairs ( Figure 2D ). The BRAFi resistance-inducing mutation NRAS Q61K Figure S4C ). This mutation has not been validated yet as a cause of resistance, but two other previously described resistance-conferring mutations, namely AKT3 E17K and AKT1 Q79K (Shi et al., 2014a (Shi et al., , 2014b , are located within the same pleckstrin homology (PH) domain as AKT3 L51R .
These mutations induce (re)localization of AKT to the membrane, causing constitutive activation of the PI3K/AKT pathway (Parikh et al., 2012) . The M048R2.X1 PDX, harboring this AKT3 L51R mutation, indeed displays highly activated AKT (Figure 2A) Figure S4D ). In contrast, M026R.X2, a PDX derived from a vemurafenib-resistant lesion from the same patient in which we identified a NRAS Q61K mutation as the resistance mechanism ( Figures S4A and S4B ), was completely resistant to BRAFi ( Figure 3A) . Consistently, p-ERK levels of M026R.X2 were unaffected by BRAFi (Figure 3B) . A similar pattern was observed for the matched M029 PDX pair: treatment-naive melanoma M029.X2 responded well to BRAFi along with p-ERK inhibition, whereas tumor outgrowth of NRAS Q61K mutant M029R.X2 and its p-ERK levels were unaffected by BRAFi (Figures 3A and 3B ; Figure S4D ). Of note, the growth rate of the (untreated) M029R.X2 was much slower than that of its treatment-naive counterpart M029.X2. This behavior was different for matched pair M009.X2/R.X2, in which the presence of the BRAF T1799A amplification correlated with therapy resistance. For this PDX set, expansion of the treatment-naive M009.X2 melanoma was reduced upon BRAFi and p-ERK levels decreased, as expected (Figures 3A and 3B; Figure S4D) . However, BRAFi also slowed down the growth and decreased p-ERK levels of M009R.X2, which was derived from a vemurafenib-resistant lesion (Figures 3A and 3B; Figure S4D (legend continued on next page) with super-amplification of BRAF T1799A . Additionally, this would suggest that the BRAF amplification and the resulting resistance can be dynamic, as has been suggested by others ). These results demonstrate concordance between drug responses in patients and their corresponding PDXs, and they illustrate that the therapy response can be either stable or dynamic. Using CopywriteR, we generated copynumber profiles from the sequencing data ( Figure 4A ). These profiles revealed a CNA pattern typical of melanoma, including gain of chromosome 7, where BRAF is located, and loss of chromosome 10, which harbors the tumor suppressor gene PTEN, both established drivers of melanomagenesis. Next we analyzed which mutations are present in our PDX panel, focusing on mutations in the 15 driver genes on which the molecular classification of melanomas has been described previously (Cancer Genome Atlas Network, 2015) ( Figure 4B ). For 11 of 15 driver genes, mutations were observed in the 53 PDX samples. The complete list of mutations identified by targeted sequencing is provided in Table S3 .
PDXs Derived from Vemurafenib-Resistant Melanomas Harbor a Plethora of Established Clinical Resistance Mechanisms
In the panel of 53 sequenced PDXs (Table S4) , 19 were derived from BRAF V600E metastatic melanomas that had acquired resistance to vemurafenib. We analyzed this PDX set for the presence of known resistance mechanisms. As discussed above, resistance to vemurafenib is commonly associated with reactivation of the MAPK pathway and/or the PI3K/AKT pathway. Concordantly, when we determined the corresponding biomarker levels in these PDXs, we found that, in most, either p-ERK or p-AKT was highly induced ( Figure 5A ; Figure S5A ). Next we analyzed BRAF expression by immunoblotting to detect alternative splice variants, which also are known to render melanomas refractory to BRAFi. These variants splice out the RAS-binding domain (RBD) of BRAF (encoded by exons 3-5), inducing dimerization of BRAF and downstream signaling without the need to be activated by RAS (Poulikakos et al., , epitope in exon 15), we detected these different splice variants in several PDXs ( Figure 5B ).
We also identified other previously detected and validated resistance mechanisms in the post-vemurafenib PDX panel, including hyperactivation of c-MET (Vergani et al., 2011), EGFR overexpression (Sun et al., 2014) , loss of PTEN ( Figure 5B), amplification of BRAF T1799A (Shi et al., 2014b) (Figure 5C) , and amplification of MITF (Garraway et al., 2005; Van Allen et al., 2014) ( Figure 5D ). Additionally, using the targeted sequencing data, we found known BRAF inhibitor resistance-conferring mutations, including MAP2K1 E203K (Nikolaev et al., 2011) , BRAF L505H , NRAS Q61K , and PIK3CA E545K (Shi et al., 2014b) ( Table S5) . Through a combination of mutational data with biochemical analyses, the cause of resistance was resolved for 13 of the 19 PDXs derived from patients with acquired resistance to vemurafenib. This also revealed that some PDXs harbor multiple resistance mechanisms (Table S5 ). For example, M056R.X1 harbored a MAP2K1 E203K mutation, alternative BRAF splicing, as well as EGFR overexpression, indicating that resistance mechanisms can be heterogeneous Shi et al., 2014b) . Our data show that this heterogeneity is captured and maintained in PDXs.
To summarize, this set of post-vemurafenib PDXs harbors a wide range of resistance mechanisms, closely recapitulating clinical samples. Some PDXs harbored multiple resistance mechanisms, a phenomenon commonly seen in melanoma, indicating that the heterogeneity of resistance can be maintained in these PDX models. melanoma, drug resistance continues to be a major obstacle for achieving durable clinical responses. To illustrate the utility of this PDX platform, we set out to screen for resistance mechanisms. We focused on those that can be discovered at the protein level, in other words, using analyses requiring substantial amounts of melanoma tumor material. Thus, we took advantage of our PDX collection serving as an unlimited source for this purpose. In addition to the previously identified resistance mechanisms described above, we noted that several PDXs derived from vemurafenib-resistant melanomas expressed an unusual BRAF V600E protein, which migrated in an SDS-PAGE gel at an apparent molecular weight of $140 kDa. It was recognized by both the BRAF we discovered similar BRAF proteins in two cell lines that had acquired resistance to MAPK pathway inhibition in vitro (PLX4720-resistant A375R and dabrafenib/trametinib double-resistant [DR] 888mel) ( Figure 6A ). Importantly, this abnormal BRAF V600E protein also was detected in corresponding patients samples of the PDXs expressing this $140-kDa BRAF V600E protein ( Figure 6B ), excluding that this was due to an in vitro or PDX artifact.
To unmask the identity of this apparently common $140-kDa BRAF V600E protein, we performed whole-genome sequencing (WGS). We observed that resistant melanoma cells harbored genomic rearrangements and partial duplication of the BRAF genomic locus: the first breakpoint was located in the intron between exons 9 and 10 of BRAF T1799A , while the second breakpoint had occurred in the intron between exons 18 and 19. The resulting duplication contained exons 10-18 of the BRAF T1799A gene, which harbors the kinase domain ( Figure 6C ; Figures  S6A-S6F ). This was confirmed by PCR using primers specifically for each breakpoint ( Figure 6D ). We also observed a larger amplification on chromosome 7 of 888melDR, raising the possibility that the locus containing BRAF T1799A with the kinase domain duplication was amplified specifically during resistance acquisition (Figures 6E and 6F; Figures S6C and S6D) . To confirm that the duplication of the BRAF T1799A kinase domain-encoding region results in the production of a BRAF V600E protein harboring a duplication of its kinase domain (hereafter BRAF V600E/DK ), we performed RNA sequencing on the four PDXs that expressed the $140-kDa protein. This revealed that, in three of the four cases, the fusion between exon 18 and exon 10 had occurred at 18 bp 5 0 to the stop codon in exon 18 and at the start at exon 10 ( Figure 6G ). This location in exon 18 recently was identified as a splice donor site ( Figure 6G ), which is used by melanoma cells to splice to an alternative X1 3 0 UTR localized in exon 19 (Marranci et al., 2015) . Melanoma cells can thus express BRAF with a normal 3 0 UTR (BRAF-N) or with an alternative X1 3 0 UTR (BRAF-X1, Figure 6G ).
This raised the possibility that, resulting from the genomic rearrangement, the BRAF V600E/DK -expressing tumors use this alternative splice donor site in exon 18 to splice to the next exon 10. We validated this predicted fusion on mRNA by RT-PCR, using a forward primer in exon 18 and a reverse primer in exon 10 ( Figure 6H ). This confirmed the presence of BRAF V600E/DK in three PDXs (M033R.X1, M063R.X1, and M048R2.X1) that showed the $140-kDa band on immunoblotting ( Figure 6A ), as well as in two vemurafenib-resistant cell lines (A375R and 888melDR). Also, we confirmed the location of the fusion by Sanger sequencing ( Figure 6I ). Furthermore, using RNA-sequencing data of an independent set of MAPK pathway inhibition-resistant melanomas , we identified the BRAF V600E/DK in four of 44 resistant tumors (Table S6) , in which no other genomic mechanism was found to explain the acquired resistance.
To validate the identity and configuration of BRAF V600E/DK independently at the protein level, we performed immunoprecipitation (IP) for BRAF on the 888melDR cell line, which showed very high expression of the endogenous BRAF V600E/DK protein.
The samples were run on an SDS-PAGE gel from which the 140-kDa band was excised and subjected to mass spectrometry. The result confirmed the findings from the genetic analyses ( Figure S7 ). Taken together, our data indicate that the genomic breakpoint can occur anywhere between exons 18 and 19 and that the tumors use an alternative splice donor site within exon 18 to splice to the next exon (which is exon 10 in the case of the BRAF V600E/DK ). This configuration allows for the natural stop codon in exon 18 to remain intact, as it is removed by splicing, resulting in an in-frame kinase domain duplication. Peng et al. (2015) have shown that a new pan-RAF dimerization inhibitor (LY3009120) inhibits various forms of BRAF dimers, including the previously described p61 BRAF isoform (Peng et al., 2015; . We treated two cell lines (A375R and PDX-derived cell line M063R.X1), both of which harbored BRAF V600E/DK , with LY3009120. Compared to treatment with vemurafenib, these cell lines were highly sensitive to treatment with LY3009120 ( Figure 7F ). -encoding RNA (1 and 2). Cells were treated for 7 days with control vehicle or 1, 3, 5, 7, or 10 mM PLX4720 or vemurafenib. Graphs depict the normalization of six independent experiments. Unpaired t test was performed for each concentration of drug (*p < 0.05, **p < 0.01, and ***p < 0.001 Next we tested the effect of the LY3009120 compound in vivo, using two PDXs (M063R.X2 and M048R2.X2) that had acquired the BRAF V600E/DK as resistance mechanism ( Figure 6A ). Both PDXs were treated either with the BRAF inhibitor dabrafenib, to which they were completely resistant ( Figures 7G and 7H ), or the pan-RAF dimerization inhibitor LY3009120. LY3009120 treatment of M063R.X2 resulted in an effective inhibition of p-ERK and thereby stable disease ( Figure 7G ). In contrast, upon LY3009120 treatment, M048R2.X2 displayed delayed tumor outgrowth only ( Figure 7H ). As shown previously, resistance mechanisms in PDX samples can be heterogeneous Van Allen et al., 2014) . Moreover, above we described that M048R2.X2 harbors an AKT3 L51R mutation in addition to the BRAF V600E/DK mutation ( Figure S4C ), which conceivably explains the reduced sensitivity to the pan-RAF dimerization inhibitor: the AKT3 L51R mutation fuels the PI3K/AKT pathway, which may reduce the effect of BRAFi. Indeed, AKT signaling was much more active in the M048R2.X2 PDX ( Figure 7I ), explaining its only partial sensitivity to LY3009120. These results warrant clinical validation of LY3009120 for treating melanoma patients harboring a BRAF V600E/DK mutation.
More generally, these findings highlight one key feature of our PDX platform.
DISCUSSION
Here we present a comprehensive and well-characterized PDX collection comprising 89 metastatic human melanomas, including a set of matched pre-treatment/post-relapse pairs. (Hoek et al., 2006; Verfaillie et al., 2015) , are better studied in an in vivo setting. Finally, to illustrate the power and utility of this platform, we have taken advantage of its limitless tumor resource, in contrast to patients' biopsies. Screening in PDX cell lysates for BRAF proteins with aberrant molecular weights, we identified a kinase domain duplication mutant of BRAF
V600E
, which drives vemurafenib resistance.
While several resistance mechanisms have been identified previously thanks to the efforts of many laboratories Shi et al., 2012 Shi et al., , 2014a Das Thakur et al., 2013; Wagle et al., 2011) , we show here that a specific genetic duplication encoding the kinase domain of BRAF V600E causes resistance to MAPK pathway inhibition. Remarkably, the genomic rearrangement, which results from intronic breaks between exons 9 and 10 and between exons 18 and 19, leaves the original stop codon present in exon 18 intact. As melanoma cells seem to preferentially use the alternative splice donor site in exon 18 to splice to the alternative X1 3 0 UTR in exon 19 (and thus use the X1 stop codon) (Marranci et al., 2015) , this conceivably explains why cells carrying the genomic duplication of the kinase domain use this splice donor site to produce the BRAF V600E/DK protein. This may imply that the splicing event can be induced by drug exposure; this would provide a selective advantage, whereas expression of BRAF V600E/DK in the absence of BRAFi would not.
Previously, others have shown that duplication of the kinase domain of RTKs, like EGFR (Gallant et al., 2015; Ozer et al., 2010) or FGFR1 , drives oncogenicity in glioblastoma, lung cancer, and gliomas, respectively. Recently, wild-type BRAF with a duplicated kinase domain was detected in a neuroblastoma tumor after chemotherapy (Eleveld et al., 2015) , but such an event has not yet been implicated in acquired resistance to targeted therapy. Further research will be required to unravel the mechanism of how BRAF V600E/DK functions at a molecular level. . Using an inhibitor that targets the BRAF V600E homodimers (Peng et al., 2015) , we were able to eliminate BRAF V600E/DK melanoma cells and effectively inhibited tumor growth of PDXs in vivo. As we identified the BRAF V600E/DK as a resistance mechanism in $10% of PDXs and patient samples, this pan-RAF dimerization inhibitor may offer a clinical opportunity for this particular subgroup of patients who have required resistance to (combined) inhibitors of the BRAF pathway, arguing that screening for this subset of patients could be beneficial.
We conclude that the PDX platform presented here reflects the original melanomas in patients very well with respect to several key characteristics, including resistance mechanisms. This platform therefore provides a relevant and comprehensive suite of well-characterized treatment-naive and -resistant melanomas, representing an invaluable toolbox for studying fundamental aspects of melanoma biology and for the development, validation, and optimization of melanoma (combinatorial) treatments, to further improve the perspective on melanoma patients.
EXPERIMENTAL PROCEDURES Patient Samples, Animals, and PDXs
The collection and use of human tissue was approved by the Medical Ethical Review Board of the Antoni van Leeuwenhoek. Animal experiments were approved by the animal experimental committee of the institute and performed according to Dutch law. Human tumor tissue was obtained either by excision during surgery or using a 14-gauge biopsy needle. Tumor fragments of $5 mm 3 were used for subcutaneous transplantation into NSG mice, which was performed under anesthesia. Before reaching the maximum allowed tumor size, mice were sacrificed, tumors were removed, and tumor pieces were (1) fixed in formalin and embedded in paraffin; (2) snap-frozen and stored at À80 C for further analyses; (3) cryopreserved in 10% fetal calf serum (FCS) in DMSO and stored at À80 C for additional passages; and (4) 
Immunoblotting and Antibodies
Immunoblotting was performed as described previously Cell Culture, Transfection, and Virus Production Melanoma cell lines and HEK293T cells were cultured in DMEM containing fetal bovine serum (FBS) (Sigma), 2 mM glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin (all Gibco) under standard conditions. Resistant cell lines were generated by treatment with increasing concentrations of PLX4720 (Selleck Chemicals, up to 3 mM) or the combination of dabrafenib (GSK2118436, Abmole, up to 0.5 mM)/trametinib (GSK1120212, S2673, Selleck Chemicals, up to 50 nM). Transfections and production of lentivirus were performed as described previously (Vredeveld et al., 2012) . A375R cells were infected and selected with puromycin (1 mg/ml). For the colony formation assays, 20,000 cells were seeded in six-well plates and indicated concentrations of PLX4720, vemurafenib, or LY3009120 were added the next day. Cells were stained by 0.1% crystal violet in 50% methanol and 50% H 2 0. After staining, de-staining by 10% acetic acid was used to quantify the number of stained cells. Color intensity was measured at 590 nm and values were normalized to DMSO control. For immunoblotting, cells were treated for 24 hr with the indicated concentrations of BRAFi.
qPCR, Sanger Sequencing, and Validation of the Presence/Cloning of BRAF V600E/DK and shRNA Generation
All primers and hairpin sequences are described in Table S7 . BRAF V600E/DK was cloned from the 888melDR cell line into a TOPO TA-cloning vector (450071, Invitrogen); we used the restriction site XbaI and SwaI to clone BRAF V600E/D into the pCDH vector. BRAF V600E/DK shRNAs were designed at the junction region between exons 18 and 10.
Statistical Testing
The data of in vivo experiments were analyzed at the last time point by an unpaired t test using the Prism software. For the colony formations assays, six independent experiments were performed. Data were normalized to the scr control for each concentration of the drug. Unpaired t tests were used (in Prism software) to compare the effect between the scr and the two hairpins for each concentration of the drug. , and Rosen, N. (2014) . Towards a unified model of RAF inhibitor resistance. Cancer Discov. 4, 27-30.
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Vergani, E., Vallacchi, V., Frigerio, S., Deho, P., Mondellini, P., Perego, P., Cassinelli, G., Lanzi, C., Testi, M.A., Rivoltini, L., et al. (2011) M029.X1 M029R.X1 Genomic breakpoints Figure S6 C. D. H&E stainings and IHC stainings for MelanA, S100, gp-100 and tyrosinase were performed on the parental tumor and two subsequent passages of PDX (X1 and X2). Scale bars indicate 100 µm. A. Vemurafenib treatment schedule for each patient from whom we obtained tumor specimens before start of treatment, during treatment or after resistance had occurred. Indicated are the time points when the samples were taken. The overall response, according to RECIST 1.1 criteria, is indicated. B. Location of each of the obtained patient samples. C. For each individual lesion, the diameter was measured at baseline (before start of treatment) and every two consecutive months during treatment until progressive disease was observed. For one patient (M019), the CT-scans of the tumor location were unavailable. Vertical dashed line indicates start of vemurafenib treatment. For three patients (M009, M029, M048), the pre-treatment PDX were derived from lesions that were surgically removed before the start of treatment and these tumors did not recur at those particular locations. One pretreatment PDX was derived from a lesion that showed a complete response (CR) to vemurafenib before it recurred (M026) According to the response data, we have grouped these PDX pairs in 1) acquired resistant 2) on treatment and 3) intrinsic resistant. Circos plots visualizing the structural variants (SV) and DNA copy number aberrations detected in parental cell line 888mel and double resistant cell line 888melDR. Blue indicates inter-chromosomal SVs, red intra-chromosomal SV. D. Circos plots visualizing the SV and DNA copy number aberrations detected in 888melDR but not in 888mel, both genome wide (top) and for the three chromosomes associated with the amplification on chromosome 7 which includes BRAF (bottom). E. Circos plot visualising the SVs and DNA copy number aberrations detected in resistant cell lines A375R. F. Read count data for A375R for the BRAF locus. Each dot represents the average number (log 2 ) of reads per 5kb. Loss of PTEN Shi et al., 2014) M014R BRAF splicing EGFR overexpression (Nikolaev et al., 2012; Prahallad et al., 2012) M060R.X1 PR 10 months PIK3CA E545K EGFR overexpression (Prahallad et al., 2012; Shi et al., 2014) M061R.X1 PR 10 months EGFR overexpression (Prahallad et al., 2012) M062R.X1 PR 12 months BRAF L505H MITF amplification (Choi et al., 2014; Van Allen et al., 2014; M063R.X1 SD 4 months M074R.X1 PD 2 months PR = partial response, SD = stable disease, CR = complete response, MR = mixed response 
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Supplemental Experimental Procedures
Response data patients CT scans were used to determine the size of independent lesions at different time points. The size of a lesion was defined as the longest in plane diameter (in mm), measured manually by the tool provided in the Inter PACS Viewing & sharing System. For consistency, every lesion was measured by the same person on all subsequent CT scans. To ensure objectivity, this person was blinded for any other data of the patient in question.
DNA isolation
DNA was isolated from granulocytes derived from peripheral blood and tumor fragments using the DNA Easy Blood & Tissue Kit (Qiagen) according to manufacturer's protocol. DNA content was measured using Picogreen (P7581) according to manufacturer's protocol.
ArrayCGH analysis DNA samples and normal genomic DNA (female, G1521, Promega) were labeled with CGH labeling kit for BAC Arrays (Enzo Life Sciences) according to manufacturer's protocol. After labeling, the samples were hybridized on a Nimblegen array (090527_HG18_WG_CGH_v3.1_HX12,_GEO platform ID: GPL17641). Image acquisition of the Nimblegen arrays was performed using the Agilent DNA Microarray Scanner (Model G2505B, Serial number US22502518) and image analysis was performed using Nimblescan software version 2.6 (Roche Nimblegen). Segmentation of all copy number profiles was calculated using circular binary segmentation (CBS) as implemented in the Rpackage CGHcall 2.22.0 (van de Wiel et al., 2011) .
Whole Genome Sequencing of cell lines DNA of parental 888mel, dabrafenib and trametinib double resistant 888mel (888melDR) and PLX4720-resistant A375 (A375R) was isolated as described above. Sequencing with 151bp paired-end reads of sequence libraries was performed on the Illumina X10 analyzer. Reads were mapped to the Sanger human reference (hg19) and BAM files were binary compressed, sorted and indexed by SAMtools (samtools view, sort and index tools), duplicated reads were removed by Picard (with MarkDuplicates) and base quality score recalibration and local realignment around indels followed the recommended workflow of the GATK toolkit (RealignerTargetCreator, IndelRealigner, BaseRecalibrator and PrintReads). Sequencing data has been made available through the European Genome-phenome Archive (EGA; http://www.ebi.ac.uk/ega/home; accession number EGAS00001001304).
Whole exome sequencing of matched PDX DNA of 21 PDX samples with matching reference (blood) was isolated as described above and subjected to whole exome sequencing. Exome enrichment was performed using the Agilent SureSelect Human Exon Kit 50Mb capture set (Agilent, G3362). Sequencing with 75bp paired-end reads of targeted-enrichment libraries was performed on an Illumina HiSeq 2000 analyzer. Reads were mapped by bwa 0-7.5 with default settings to the human reference (hg19) and mouse reference (mm10), the latter for later removal of reads from mouse origin, as described below. BAM files were processed using Picard [1.101], SAMtools [0.1.18] and the Genome Analysis ToolKit (GATK) release 2.7-4. BAM files were binary compressed, sorted and indexed by SAMtools (samtools view, sort and index tools), duplicated reads were removed by Picard (with MarkDuplicates) and base quality score recalibration and local realignment around indels followed the recommended workflow of the GATK toolkit (RealignerTargetCreator, IndelRealigner, BaseRecalibrator and PrintReads). BAM files were further processed by removing reads that originate from mouse with XenofilteR release version 1.3 (https://github.com/PeeperLab/XenofilteR, Kluin and Krijgsman, manuscript in preparation. For each read-pair we summed the number of soft-clips, mismatches and inserts, both for mapping against the human as well as the mouse reference. The derived scores were used to classify reads as either mouse or human. Only reads with a lower score in human compared to mapping to mouse were retained in the final bam files.
Variants were called by GATK 2.7-4 using the 'UnifiedGenotyper' with default settings except for "-minIndelFrac" which was set to 10%. Annotation of the vcf files was performed with ANNOVAR (release 2014, October) (http://www.openbioinformatics.org/annovar/). All variants detected in the germ-line (blood) samples with a Variant Allele Frequency (VAF) over 5% were excluded from further analysis. Variants were further filtered: minimum VAF of 5% in at least one of the samples; a minimum of 10x coverage in a least one of the samples; variant positions must not be listed as a single nucleotide polymorphism (SNP) in the 1000 Genome project except when present in COSMIC; Variant position must be annotated as exonic by RefSeq (Release 45); synonymous/non-synonymous calls were made and the synonymous excluded from further analysis. All filtering was performed with R 3.1.1 using in-house parsers. Sequencing data has been made available through the European Genomephenome Archive (EGA; http://www.ebi.ac.uk/ega/home; accession number EGAS00001000415 and EGAS00001000617).
Targeted sequencing of unmatched PDX DNA of 48 PDX samples was isolated as described above and subjected to targeted sequencing of 360 established and putative cancer-related genes using custom-made bait set (Agilent Technologies) for target enrichment. Paired-end sequencing was performed on Illumina HiSeq 2000 or 2500 analyzers. The raw sequence reads were processed similar to the WES data with the difference that no blood reference was available. The observed variants were referenced with polymorphisms catalogued by the 1000 genomes project (1000 Genomes Project Consortium et al., 2010 to remove known germline variants. Sequencing data has been made available through the European Genome-phenome Archive (EGA; http://www.ebi.ac.uk/ega/home; dataset ID: study ID: EGAS00001000655) DNA copy number profiles BAM files from targeted sequencing and whole exome sequencing were analyzed for DNA copy number aberrations by CopywriteR . DNA copy number profiles of matched PDX samples, analyzed with whole exome sequencing, were generated with 20kb bins, resulting in ~137K data points evenly distributed over the genome. Log 2 ratios were calculated for tumor samples versus reference (blood) sample.
DNA copy number profiles of unmatched PDX samples, analyzed with targeted sequencing, were generated with 100kb bins, resulting in ~25K data points evenly distributed over the genome. Log 2 values were calculated based on tumor samples without a reference as described in .
DNA copy number profiles of cell lines 888mel, 888melDR and A375R, analyzed with WGS, were generated with 5kb bins evenly distributed over the genome. The resulting read count data was normalized similar to the WES data by loess normalization based on GC-content and mappability. Differences in DNA copy number between parental 888mel and 888melDR were assessed by subtracting the log2 of the read count of 888mel from the log2 read count of 888melDR. All normalized profiles were further analyzed by circular binary segmentation (CBS) (Venkatraman and Olshen, 2007) .
Structural variation in WGS
Structural variations in cell lines 888mel, 888melDR and A375R were assessed directly on the WGS bam files with breakdancer (Chen et al., 2009) . Only structural variants with a confidence score of 99 and a minimum of 10 supporting reads were used for the analysis. In addition, the minimum length between 2 intra-chromosomal breakpoints was set to 1mb. To assess the difference between 888mel and 888melDR all structural variants present in 888mel were removed from the list of structural variations in 888melDR. Circos plots were generated with using the DNA copy number data as described above and the filtered list of structural variations.
RNA isolation and sequencing
RNA isolated by Trizol, according to manufacturers protocol, from Fresh-Frozen (FF) PDX samples and Formalin-Fixed, Paraffin-Embedded (FFPE) patient archival tissue was sequenced with 50bp single-end sequencing on an Illumina HiSeq2000. Read counts per gene were quantified using HTSeq version 0.5.4. Read mapping was performed using TopHat version 2.0.9 with the NCBI Build 37 reference genome. Read counts were transformed by applying a variance stabilization with DESeq (1.12.1). In DESeq the dispersion estimate estimateDispersions had parameters: method 'per-condition' and fitType 'local' and for null model evaluation with no replicates method 'blind', and sharingMode 'fit-only'. Gene expression differences between PDX (FF) and patient (FFPE) read count data were observed by cluster analysis. Of the 21.467 genes in the initial analysis 1399 genes were differentially expressed (FDR<0.2) between the PDX and patient samples. After removal of these 1,399 genes the samples were clustered again with the remaining 20,068 genes. Heatmaps were generated with gplots (2.12.1) as available through Bioconductor. Analysis was performed, and plots were made using the statistical programming language R (v 3.0.2).
RNA isolated from 4 FF PDX samples (M010R.X1, M033R.X1, M063R.X1 and M048R2.X1) was sequenced with 65bp paired-end sequencing on an Illumina HiSeq 2500. Discordant read pairs with both reads mapping within in BRAF were identified from the Tophat 'fusions.out' file and visually inspected in IGV to verify the breakpoints associated with the BRAF V600E kinase duplication. Both RNA sequence data sets are available through accession number GSE73738.
Raw data (fastq) from an independent dataset were downloaded from NCBI's Sequence Read Archive (SRA, SRP052740). Read mapping was performed using TopHat version 2.0.9 with the NCBI Build 38 reference genome. Discordant read pairs with both reads mapping within in BRAF were identified from the Tophat 'fusions.out' file and visually inspected in IGV to verify the breakpoints associated with the BRAF V600E kinase duplication.
FISH
Preparation of metaphase chromosome spread from parental Mel888 and double resistance Mel888 was performed as previously described (van Steensel et al., 1998) .Two-color metaphase FISH was performed using chromosome 7 centromere probe (Chr7 CEP GR, G100527G-8, Agilent) and BRAF probe (7q34 BRAF-CN RD, G100368R-8, Agilent) according to the manufacturer's protocol.
Mass-spectrometry analysis of BRAF V600E/DK
Mouse-anti-B-RAF (F7, Santa Cruz) antibodies were cross-linked to Dynabeads protein G (Cat #:10003D) according to the manufacturer's instruction. Cell lysates were incubated with these Dynabeads for 2h at 4°C. After washing 5 times with immunoprecipitation (IP) buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1.0% NP-40), elution was performed by boiling in NaPAGE LDS sample buffer (NP0008, Novex) and then processed for SDS-PAGE. Following staining of the SDS-PAGE gel with GelCode Blue stain (Pierce), the BRAF V600E/DK protein band was excised, proteins in the gel plug were reduced with DTT (1 hr at 60 0 C) and subsequently alkylated using iodoacetamide (30 min at RT in the dark). In-gel digestion with 3ng/uL trypsin (Gold, Mass Spectrometry Grade, Promega) in 50 mM ammonium bicarbonate (pH 8.5) was performed overnight at 37 o C. After digestion, peptides were extracted with acetonitrile and dried down in a speed vacuum centrifuge. Prior to mass spectrometry analysis, the peptides were reconstituted in 10% formic acid.
Peptides were separated using the Proxeon nLC 1000 system (Thermo Scientific, Bremen) fitted with a trapping (ReproSil-Pur 120 C18-AQ 3µm (Dr. Maisch GmbH, Ammerbuch, Germany); 100 µm x 30 mm) and an analytical column (ReproSil-Pur 120 C18-AQ 2.4 µm (Dr. Maisch GmbH); 75 µm x 500 mm), both packed in-house. The outlet of the analytical column was coupled directly to a Thermo Orbitrap Fusion hybrid mass spectrometer (Q-OT-qIT, Thermo Scientific) using the Proxeon nanoflex source. Nanospray was achieved using a distally coated fused silica tip emitter (generated in-house, o.d. 375 µm, i.d. 20 µm) operated at 2.1 kV. Solvent A was 0.1% formic acid/water and solvent B was 0.1% formic acid/ACN. An aliquot (25%) of the in-gel digest was eluted from the analytical column at a constant flow rate of 250 nl/min in a 35-min gradient, containing a linear increase from 7% to 25% solvent B, followed by wash at 80% solvent B. Survey scans of peptide precursors from m/z 375-1500 were performed at 120K resolution with a 4 x 10 5 ion count target. Tandem MS was performed by quadrupole isolation at 1.6 Th, followed by HCD fragmentation with normalized collision energy of 33 and ion trap MS 2 fragment detection. The MS 2 ion count target was set to 10 4 and the max injection time was set to 50 ms. Only precursors with charge state 2-6 were sampled for MS 2 . Monoisotopic precursor selection was turned on; the dynamic exclusion duration was set to 30s with a 10 ppm tolerance around the selected precursor and its isotopes. The instrument was run in top speed mode with 3 s cycles.
Raw data files were processed using Proteome Discoverer (version 1.4.1.14, Thermo Fisher Scientific). MS 2 spectra were searched against a custom database containing contaminants and the predicted sequence of the BRAF V600E/DK protein using Mascot (version 2.4.1, Matrix Science, UK). Carbamidomethylation of cysteines was set as fixed modification and oxidation of methionine was set as a variable modification. Trypsin was specified as enzyme and up to two miscleavages were allowed. Data filtering was performed using percolator, resulting in 1% false discovery rate (FDR), and peptide ion score >20.
